Rifampicin at High Dose for Difficult-to-Treat Tuberculosis
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of rifampicin given at a dose three times
as the standard one, in persons with tuberculosis that belong to groups that have not been
widely included in previous trials.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Collaborators:
Centro Hospitalar De São João, E.P.E. Instituto Nacional de Enfermedades Respiratorias y del Ambiente, Paraguay Radboud University University Medical Center Groningen